RAPP (Rapport Therapeutics) EV-to-FCF : -0.79 (As of Mar. 20, 2025)

Rapport Therapeutics EV-to-FCF Chart

Competitive Comparison of Rapport Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Rapport Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapport Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Rapport Therapeutics's EV-to-FCF falls into.

Rapport Therapeutics EV-to-FCF Calculation

Rapport Therapeutics's EV-to-FCF for today is calculated as:

Rapport Therapeutics's current Enterprise Value is $53.13 Mil.
Rapport Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics  (NAS:RAPP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Rapport Therapeutics's PE Ratio (TTM) for today is calculated as:

Rapport Therapeutics's share price for today is $10.12.
Rapport Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Rapport Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description